newsfilter
← Latest News
Business Wire·

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

- AMX0035 did not show differences compared to placebo on primary or secondary outcomes at Week 24 - AMX0035 continued to be generally well-tolerated Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the